Science 37 Holdings

Science 37 Holdings, Inc. provides technology-based solutions that enables decentralized clinical trials. The company is headquartered in Durham, NC.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results for the quarter ended September 30, 2022.

Science 37 Reports Third Quarter 2022 Financial Results

RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report third quarter 2022 financial results after the market closes on Thursday, November 10, 2022. Company management will host a corresponding conference call on Friday, November 11, 2022, at 8:30 a.m. Eastern Time.

Science 37 to Report Third Quarter 2022 Financial Results on November 10, 2022

Former Chief Information officer and Executive Committee member for Bristol Myers Squibb brings deep industry and technology expertise to Science 37 Former Chief Information officer and Executive Committee member for Bristol Myers Squibb brings deep industry and technology expertise to Science 37

Science 37 appoints Paul von Autenried to its Board of Directors

Shipton joins Science 37 to help capitalize on the high demand for decentralized clinical trials and drive further growth into enterprise opportunities Shipton joins Science 37 to help capitalize on the high demand for decentralized clinical trials and drive further growth into enterprise opportunities

Science 37 Names Industry Veteran Michael Shipton as Chief Commercial Officer

RESEARCH TRIANGLE PARK, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Science 37® Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced the company will be participating in the upcoming Baird Global Healthcare Conference in New York.

Science 37 to Present at the Baird 2022 Global Healthcare Conference

By following the patient, home-based data collection enables more clinical trials to adopt agile (hybrid) and fully decentralized approaches. By following the patient, home-based data collection enables more clinical trials to adopt agile (hybrid) and fully decentralized approaches.

Science 37 and NuvoAir Partner to Bring Patient-Centric Experience to Respiratory Clinical Trials

Patient relationship management and contact center technology enables Science 37 to achieve significantly greater patient engagement Patient relationship management and contact center technology enables Science 37 to achieve significantly greater patient engagement

New Science Technology Accelerates Patient Recruitment and Enrollment

New Science 37 Technology Accelerates Patient Recruitment and Enrollment

Oncology patients and clinical research sponsors benefit from Syapse's real-world data intelligence and Science 37's agile trial operating system to help accelerate the identification and participation of eligible participants Oncology patients and clinical research sponsors benefit from Syapse's real-world data intelligence and Science 37's agile trial operating system to help accelerate the identification and participation of eligible participants

Science 37 and Syapse Partner to Enable Faster Patient Enrollment in Oncology Clinical Trials

Science 37 Holdings, Inc. (NASDAQ:SNCE ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Caroline Paul - Investor Relations David Coman - Chief Executive Officer Mike Zaranek - Chief Financial Officer Conference Call Participants Charles Rhyee - Cowen Justin Lin - William Blair Matt Hewitt - Craig-Hallum Frank Takkinen - Lake Street Operator Hello, thank you for standing by and welcome to the Science 37 Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Science 37 Holdings, Inc. (SNCE) CEO David Coman on Q2 2022 Results - Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results for the quarter ended June 30, 2022.

Science 37 Reports Second Quarter 2022 Financial Results

RESEARCH TRIANGLE PARK, N.C., July 28, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report second quarter 2022 financial results before the market opens on Thursday, August 11, 2022. Company management will host a corresponding conference call at 8:30 a.m. Eastern Time.

Science 37 to Report Second Quarter 2022 Financial Results on August 11, 2022

Almost three in four (73%) oncology research executives plan to execute either a fully decentralized or hybrid clinical trial in the next 12 months Almost three in four (73%) oncology research executives plan to execute either a fully decentralized or hybrid clinical trial in the next 12 months

Oncology Clinical Trial Execs to Increase Decentralization, Science 37 Survey Indicates

RESEARCH TRIANGLE PARK, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced the company will be participating in the following virtual investor conferences.

Science 37® to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced the company will be participating in the upcoming William Blair Growth Stock Conference in Chicago.

Science 37® to Present at the William Blair 42nd Annual Growth Stock Conference

New offering provides access to patients beyond the existing site network can be implemented in four weeks. New offering provides access to patients beyond the existing site network can be implemented in four weeks.

Science 37 Introduces Virtual Site Model to Rescue Slow Enrolling Clinical Trials

New release sets the bar as the most comprehensive platform to orchestrate decentralized study conduct—unifying stakeholder journeys, increasing compliance, and generating the highest-quality data for agile trial designs requiring remote and on-premise management New release sets the bar as the most comprehensive platform to orchestrate decentralized study conduct—unifying stakeholder journeys, increasing compliance, and generating the highest-quality data for agile trial designs requiring remote and on-premise management

Science 37® Extends Leadership in Decentralized Clinical Trial Market with NextGen SaaS Release to Fully Orchestrate Decentralized Study Conduct

Science 37 Holdings, Inc. (NASDAQ:SNCE ) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Caroline Paul - Investor Relations David Coman - Chief Executive Officer Mike Zaranek - Chief Financial Officer Conference Call Participants Eric Coldwell - Robert W. Baird & Co. Justin Lin - William Blair Frank Takkinen - Lake Street Capital Markets Operator Good morning, ladies and gentlemen, and welcome to Science 37's Earnings Conference Call for the Quarter Ended March 31, 2022.

Science 37 Holdings, Inc. (SNCE) CEO David Coman on Q1 2022 Results - Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results for the quarter ended March 31, 2022.

Science 37 Reports First Quarter 2022 Financial Results

RESEARCH TRIANGLE PARK, N.C., April 25, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report first quarter 2022 financial results before the market opens on Monday, May 9, 2022. Company management will host a corresponding conference call at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time.

Science 37 to Report First Quarter 2022 Financial Results on May 9, 2022

Addition of Dr. Beg provides Science 37 with expertise to apply more decentralized clinical trial methodologies to the industry's largest therapeutic area. Addition of Dr. Beg provides Science 37 with expertise to apply more decentralized clinical trial methodologies to the industry's largest therapeutic area.

Science 37® Adds Acclaimed Researcher and Oncologist, Dr. Shaalan Beg to Bolster Therapeutic Depth

LifeSci Acquistion Corp.

Science 37 Holdings, Inc. (SNCE) CEO David Coman on Q4 2021 Results - Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C., March 22, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results for the quarter and full year ended December 31, 2021.

Science 37 Reports Fourth Quarter and Full Year 2021 Financial Results

RESEARCH TRIANGLE PARK, N.C., March 08, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report fourth quarter and full year 2021 financial results before the market opens on Tuesday, March 22, 2022. Company management will host a corresponding conference call at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time.

Science 37 to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022

Within CNS indications, data suggest Agile Clinical Trials™ and decentralized approaches will become more prevalent in 2022 and beyond Within CNS indications, data suggest Agile Clinical Trials™ and decentralized approaches will become more prevalent in 2022 and beyond

News for Science 37 Holdings Stock (SNCE)